Postrelapse survival is plotted from the time of relapse according to various features present at baseline or relapse. (A) Postrelapse survival (PRS) by GEP-defined risk at relapse. PRS was shorter among patients with GEP-defined high-risk status at relapse. (B) PRS by GEP-defined risk in the context of GEP data at both baseline before therapy and at relapse. PRS was superior in the absence of high risk at both observation times. Among the 28 patients relapsing with high-risk status, the presence of high risk also at baseline identified 12 patients with very poor prognosis. P values are as follows: a versus b, P = .029; b versus c, P = .808; a versus c, P = .004; b versus d, P = .199; a versus d, P < .001; c versus d, P = .079. (C) PRS by GEP-defined molecular subgroup designation at relapse. PRS was significantly shorter among patients with MS, MF, and PR (proliferation) designations. (D) PRS according to the duration of the preceding partial response (PR). PRS is significantly shorter in case the duration of preceding partial response was shorter than 2 years. (E) PRS according to the duration of the preceding partial response (PR) in the context of GEP-derived risk designation at relapse. P values are as follows: a versus b, P = .474; b versus c, P = .098; a versus c, P = .052; b versus d, P < .001; a versus d, P < .001; c versus d, P = .026.